Radioimmunotherapy ( RIT RIT ) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8‐year follow‐up data of 281 patients from the international RIT RIT ‐registry

摘要

Summary To assess efficacy of radioimmunotherapy ( RIT ) in follicular lymphoma, data from 281 patients collected in the RIT Network, with a median follow‐up of 8·2?years after RIT were analysed. RIT was given at first line in 18·5% and at relapse in 81·5%. Following first line therapy, 76·9% achieved complete remission ( CR ), 9·6% partial remission ( PR ), 1·9% stable disease ( SD ) and 1·9% had progressive disease ( PD ); response was not documented in 9·7%. At relapse, the rate of CR was 48·5% and that of PR was 16·6%, SD 2·6% and PD 10·5%; response was not documented in 21·8%. After median follow‐up of 8·2?years, median progression‐free survival ( PFS ) for all was 2·54?years, median overall survival ( OS ) was not reached. Median PFS and OS (both not reached) were significantly better in first line, compared to RIT at relapse ( PFS , 2·11?years; OS , 10·8?years; P ?=?0·0037 and P ?=?0·0021, respectively). Overall 8‐year PFS was 33·9%, 53·6% for first line and 29·6% for relapsed individuals. Overall 8‐year OS was 58·8%, 78·1% for first line and 54·5% for relapsed patients. Thirty‐five patients (12·5%) developed secondary malignancy and 16 patients (5·7%) experienced transformation into aggressive lymphoma. RIT is a safe and effective treatment option for follicular lymphoma, both at front line and relapse with an 8‐year PFS of 53·6% and 29·6%, respectively.